Clinical Trials Directory

Trials / Terminated

TerminatedNCT01760161

Bilateral Dual Transversus Abdominis Plane Block for Robotic Assisted Laparoscopic Surgery

A Randomised, Double-blind Study to Evaluate the Effect of Bilateral Dual Transversus Abdominis Plane Block on Postoperative Pain and Plasma Concentration of Ropivacaine After Robotic Assisted Laparoscopic Surgery

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Aalborg University Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To evaluate the effects of bilateral dual transversus abdominis plane block on postoperative pain after robotic assited laparoskopic surgery and measure the plasma-level of ropivacain after the bilateral dual transversus abdominis plane block.

Detailed description

After randomisation patients for robotic assisted laparoscopic surgery will receive bilateral dual transversus abdominis plane block containing either ropivacain or isotonic potassium chloride. The investigators will record pain-score, opioid-consumption and sensibility on the abdominal wall in the postoperative periode. Also a blood sample will be taken at 15, 30, 60, 120 and 240 minutes after the block in order to measure the plasma-level of ropivacain after bilateral dual transversus abdominis plane block. The investigators assume that there will be significant effect on postoperative pain and that the level of plasma-ropivacain will be acceptable.

Conditions

Interventions

TypeNameDescription
DRUGRopivacaineRopicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
DRUGIsotonic potassium chlorideIsotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.

Timeline

Start date
2014-04-01
Primary completion
2015-12-01
Completion
2016-02-01
First posted
2013-01-04
Last updated
2015-05-12

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01760161. Inclusion in this directory is not an endorsement.